story of the week
Efficacy and Safety of Ultra–Rapid Acting vs Rapid-Acting Insulin Analogs in People With Type 1 or Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes Technology & Therapeutics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Are New Ultra-Rapid-Acting Insulins Associated with Improved Glycemic Control and Reduced Hypoglycemia in Comparison to Conventional Rapid-Acting Insulins for Individuals with Type 1 and Type 2 Diabetes? A Systematic Review and Meta-Analysis
Diabetes Technol. Ther. 2024 Aug 01;26(8)575-586, R Villar-Taibo, A Galdón Sanz-Pastor, E Fernández-Rubio, D Barajas Galindo, A Simó Servat, FJ Ampudia-BlascoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.